Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
02 09 2022
02 09 2022
Historique:
received:
06
02
2022
accepted:
16
08
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1.
Identifiants
pubmed: 36056181
doi: 10.1038/s42003-022-03849-0
pii: 10.1038/s42003-022-03849-0
pmc: PMC9439265
doi:
Substances chimiques
Membrane Glycoproteins
0
Spike Glycoprotein, Coronavirus
0
Viral Envelope Proteins
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
903Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
J Med Virol. 2022 May;94(5):1821-1824
pubmed: 34936120
N Engl J Med. 2022 Jun 30;386(26):2526-2528
pubmed: 35704428
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Emerg Microbes Infect. 2022 Dec;11(1):477-481
pubmed: 35034583
Sci Rep. 2021 Nov 23;11(1):22777
pubmed: 34815503
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705
pubmed: 34882654
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
PLoS One. 2021 Jul 2;16(7):e0253977
pubmed: 34214116
J Infect Dis. 2022 Jun 1;225(11):1909-1914
pubmed: 34979030
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119
pubmed: 35858386
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
N Engl J Med. 2022 Mar 17;386(11):1088-1091
pubmed: 35081298
Viruses. 2021 Jul 12;13(7):
pubmed: 34372553
J Med Virol. 2022 Apr;94(4):1330-1335
pubmed: 34845730
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
BMJ. 2021 Dec 20;375:n3105
pubmed: 34930779
Front Immunol. 2021 Jul 12;12:701501
pubmed: 34322129
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Nature. 2021 Dec;600(7889):530-535
pubmed: 34670266
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376